These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2906416)

  • 1. Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex.
    Pierce PA; Peroutka SJ
    Neurosci Lett; 1988 Dec; 95(1-3):208-12. PubMed ID: 2906416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex.
    Pierce PA; Peroutka SJ
    Psychopharmacology (Berl); 1989; 97(1):118-22. PubMed ID: 2540505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors.
    Lyon RA; Glennon RA; Titeler M
    Psychopharmacology (Berl); 1986; 88(4):525-6. PubMed ID: 2871581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discriminative stimulus properties of (+/-)-3,4-methylenedioxymethamphetamine and (+/-)-3,4-methylenedioxyamphetamine in pigeons.
    Evans SM; Johanson CE
    Drug Alcohol Depend; 1986 Oct; 18(2):159-64. PubMed ID: 2877843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral effects of (+-) 3,4-methylenedioxyamphetamine (MDA) and (+-) 3,4-methylenedioxymethamphetamine (MDMA) in the pigeon: interactions with noradrenergic and serotonergic systems.
    Nader MA; Hoffmann SM; Barrett JE
    Psychopharmacology (Berl); 1989; 98(2):183-8. PubMed ID: 2569215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of (+/-)-methylenedioxymethamphetamine and (+/-)-methylenedioxyamphetamine in monkeys trained to discriminate (+)-amphetamine from saline.
    Kamien JB; Johanson CE; Schuster CR; Woolverton WL
    Drug Alcohol Depend; 1986 Oct; 18(2):139-47. PubMed ID: 2877841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulus effects of N-monoethyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDE) and N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane (N-OH MDA) in rats trained to discriminate MDMA from saline.
    Glennon RA; Misenheimer BR
    Pharmacol Biochem Behav; 1989 Aug; 33(4):909-12. PubMed ID: 2575759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulus properties of 1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDA) analogs.
    Glennon RA; Yousif M; Patrick G
    Pharmacol Biochem Behav; 1988 Mar; 29(3):443-9. PubMed ID: 2896360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain.
    Steele TD; Nichols DE; Yim GK
    Biochem Pharmacol; 1987 Jul; 36(14):2297-303. PubMed ID: 2886126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Actions of amphetamine derivatives and cathinone at the noradrenaline transporter.
    Cleary L; Docherty JR
    Eur J Pharmacol; 2003 Aug; 476(1-2):31-4. PubMed ID: 12969746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral effects of N-ethyl-3,4-methylenedioxyamphetamine (MDE; "EVE").
    Boja JW; Schechter MD
    Pharmacol Biochem Behav; 1987 Oct; 28(2):153-6. PubMed ID: 2891144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites.
    Battaglia G; Brooks BP; Kulsakdinun C; De Souza EB
    Eur J Pharmacol; 1988 Apr; 149(1-2):159-63. PubMed ID: 2899513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methysergide potentiates the hyperactivity produced by MDMA in rats.
    Gold LH; Koob GF
    Pharmacol Biochem Behav; 1988 Mar; 29(3):645-8. PubMed ID: 2896363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. (+/-)3,4-Methylenedioxymethamphetamine (MDMA) produces long-term reductions in brain 5-hydroxytryptamine in rats.
    Mokler DJ; Robinson SE; Rosecrans JA
    Eur J Pharmacol; 1987 Jun; 138(2):265-8. PubMed ID: 2887440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ecstacy: a review of MDMA and MDA.
    Climko RP; Roehrich H; Sweeney DR; Al-Razi J
    Int J Psychiatry Med; 1986-1987; 16(4):359-72. PubMed ID: 2881902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of dopamine release by methylenedioxymethamphetamine is mediated by serotonin.
    Gazzara RA; Takeda H; Cho AK; Howard SG
    Eur J Pharmacol; 1989 Sep; 168(2):209-17. PubMed ID: 2575036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
    Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDMA: further evidence that its action in the medial prefrontal cortex is mediated by the serotonergic system.
    Pan HS; Wang RY
    Brain Res; 1991 Jan; 539(2):332-6. PubMed ID: 1675911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectral and inhibitory interactions of (+/-)-3,4-methylenedioxyamphetamine (MDA) and (+/-)-3,4-methylenedioxymethamphetamine (MDMA) with rat hepatic microsomes.
    Brady JF; Di Stefano EW; Cho AK
    Life Sci; 1986 Oct; 39(16):1457-64. PubMed ID: 2877380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MDMA (3,4-methylenedioxymethamphetamine): proceedings of the conference. May 17-18, 1986, Oakland, California.
    J Psychoactive Drugs; 1986; 18(4):287-379. PubMed ID: 2880942
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.